activated and participate in transplant rejection, they must first receive a signal through the T-cell receptor (TCR), which occurs after either direct or indirect recognition of alloantigens on the surface of antigenpresenting cells (APCs). However, in order for T cells to become fully activated and acquire effector function, such as the ability to produce cytokines, they must also receive signals from the interaction of costimulatory molecules expressed on their surface with ligands expressed on APCs. Costimulatory molecule interactions can result in T-cell activation or inhibition. For example, following TCR ligation, the interaction of the costimulatory molecule CD28
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* Transduction of dendritic cells with genes encoding immunomodulatory proteins can moderately prolong graft survival. * Improved graft survival through antiapoptotic and antiproliferative gene therapy.
Prospects
* Better understanding of activation of alloreactive cells will allow for the development of more targeted gene therapy aimed at preventing this activation. * Increased understanding of costimulatory pathways will reveal additional targets for gene therapy interventions. * Elucidation of the nature of regulatory cells may lead to gene therapy approaches designed to efficiently generate these populations. * Induction of tolerance through molecular chimerism will be tested in large animal models. * Development of improved vectors for transduction of terminally differentiated tissue will improve efficacy of gene therapy approaches that depend on intracellular protein expression.
expressed on T cells with CD80 and CD86 (B7.1 and B7.2, respectively) expressed on APCs results in T-cell activation (reviewed in Sharpe and Freeman 1 ). In contrast, signaling through cytolytic T-lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells following ligation by CD80 and CD86 downregulates immune responses.
T cell costimulatory pathways are central to T-cell activation, and therefore several groups have tried to block or manipulate these pathways using gene therapy approaches in order to prevent T-cell responses. Blocking the interaction of CD28 with CD80 and CD86 using an immunoglobulin fusion protein containing the extracellular portion of CTLA-4 (CTLA-4Ig) can result in immunosuppression in vivo, and prevent transplant rejection. To overcome systemic immunosuppression as a consequence of CTLA-4Ig administration, groups have tried to prevent transplant rejection by expressing CTLA-4Ig locally within transplanted tissues or organs. Expression of the gene encoding CTLA-4Ig in donor organs has generally resulted in the prolongation of transplant survival, but has not permitted permanent acceptance (reviewed in Guillot et al 2 ). Recently, indefinite graft survival was achieved in a cardiac transplantation model. 3 However, in this model, it is likely that the transplanted organs themselves may have participated in the maintenance of hyporesponsiveness that was initially induced by transient expression of CTLA-4Ig. Indeed, cardiac allografts themselves can be tolerogenic. In experimental systems involving transplantation of tissues expressing CTLA-4Ig which are not thought to be tolerogenic, such as skin, 4 hepatocytes, 5 corneal grafts, 6 and fetal cardiomyocytes, 7 only modest graft prolongation was achieved. In these studies, graft rejection was associated with a loss or decrease in gene expression. Analysis of rat cardiac allografts expressing adenovirus encoded CTLA-4Ig revealed that while permanent acceptance of the genetically modified transplants could be achieved in allogeneic hosts, acceptance was associated with nonspecific inhibition of T-cell responses to unrelated third-party antigens. 3 Responses to third-party antigens were diminished immediately after transplantation, and hyporesponsiveness was apparent even after a five-fold reduction in serum levels of CTLA-4Ig was observed 120 days after transplantation. These data suggest that intragraft expression of CTLA-4Ig can result in systemic immunosuppression, and therefore long-term expression of this gene product may be detrimental to host immunity. In an attempt to overcome the long-term immunosuppressive effects of CTLA-4Ig expression, adenovirus vectors carrying the gene encoding CTLA-4Ig flanked by two loxP sequences were developed. 8 Following intravenous injection of adenoviruses carrying this novel CTLA-4Ig gene construct, subsequent administration of adenoviruses carrying the gene encoding Cre recombinase permitted excision of the CTLA-4Ig gene, terminating expression in vivo and vitro. Pancreatic islets transplanted into the liver of mice receiving loxP-flanked adenovirus encoded CTLA-4Ig remained functional 40 days after serum CTLA-4Ig was no longer detectable following Cre-mediated excision of the CTLA-4Ig gene. 8 However, long-term islet function after cessation of CTLA-4Ig expression was not examined, so it is not possible to determine if long-term survival occurred. Skin allograft survival was also prolonged, however, all skin grafts were eventually rejected. In addition, Cre-mediated deletion of CTLA-4Ig was associated with the restoration of responses to adenovirus, suggesting that long-term hyporesponsiveness was averted using this approach, effectively allowing one to control the duration of immunosuppression.
Gene therapy-mediated CD40/CD154 (CD40 ligand) costimulatory blockade can prevent acute allograft rejection, but does not prevent chronic alloreactivity
In addition to the CD28-CD80/86 costimulatory pathway discussed above, the interaction of CD40 ligand (CD154) expressed on T cells with CD40 on APCs has also been shown to be an important component in the initiation and maintenance of T-cell responses. Gene therapy approaches have been developed in which an adenovirus encoded CD40-Ig fusion protein is used to block intragraft CD40-CD154 interactions in order to prevent graft rejection. Adenoviral-mediated transfer of the gene encoding CD40-Ig into rat livers resulted in long-term survival following transplantation into allogeneic recipients. Immunocompetence was tested by analyzing skin allograft survival 120 days after liver transplantation, long after CD40-Ig production had ceased. Therefore, it is unclear whether recipients were able to respond to third-party antigens at earlier time points while CD40-Ig was expressed in the transplanted livers. Expression of CD40-Ig in rat cardiac transplants has also been shown to delay acute rejection, although, at early time points after transplantation, recipients of gene-modified hearts exhibited nonspecific immunosuppression. 10 At later time points, nonspecific immunosuppression abated and responses to third-party alloantigens were restored. However, when immune responses to third-party antigens were restored, antidonor T-cell activity returned in these animals, and was associated with chronic rejection. 10 The development of chronic rejection suggests that intragraft expression of CD40-Ig needs to be complemented by other therapeutic strategies to obtain long-term transplant survival.
Several other molecules involved in T-cell costimulation have recently been identified, but the function of many newly discovered costimulatory pathways has not been fully elucidated. 1, 11 However, it is becoming apparent that other costimulatory pathways, such as the inducible costimulator (ICOS)-B7 related protein-1 (B7RP-1) pathway, are important for the activation of effector T cells. 12 Indeed, it has been shown that an ICOSIg recombinant protein used in conjunction with the CD40/CD154 blockade may prevent chronic rejection of cardiac allografts. 13 While no gene transfer approach targeting ICOS-B7RP-1 interactions has been described to date, inhibiting this costimulatory pathway may represent an interesting approach for preventing chronic graft rejection.
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Hyporesponsiveness to virally encoded MHC genes has been induced in both rodent and large animal models
It has been known for many years that a state of mixed host-donor hematopoietic cellular chimerism, induced by allogeneic bone marrow transplantation, leads to long-term stable donor-specific tolerance (reviewed in Sykes 14 )
. Building on the concept of mixed chimerism, it has been suggested that a state of molecular chimerism involving the transfer of genes encoding allogeneic donor-type MHC proteins, or other antigens, into autologous hematopoietic stem cells may also result in tolerance. 15 The induction of molecular chimerism through genetic modification of autologous hematopoietic stem cells has the potential to induce donor-specific tolerance without the complications associated with allogeneic bone marrow transplants, such as graft-versus-host disease. Expression of retrovirally transduced allogeneic donor-type MHC genes in bone marrow-derived cells has been shown to be sufficient to induce donor-specific hyporesponsiveness to the introduced gene product, allowing for prolonged survival of cardiac and skin allografts without affecting rejection of third-party control grafts. 15 Hyporesponsiveness to allogeneic renal transplants has also been induced in pigs following induction of molecular chimerism, although it is not clear to what extent the transplanted organ itself contributed to establishing allograft acceptance. 16 The induction of hyporesponsiveness to marker genes expressed in bone marrow-derived cells has also been achieved in rhesus macaques. 17 Thus, the induction of molecular chimerism has been shown to be capable of inducing hyporesponsiveness in multiple animal models.
Induction of stable long-term T-cell tolerance to MHC class I antigens through central deletion of alloreactive T cells following induction of molecular chimerism
The ability to induce hyporesponsiveness through molecular chimerism has been well established; however, it has also been shown that this hyporesponsiveness can be abrogated by providing T-cell help (reviewed in Bagley et al 15 ). In order for molecular chimerism to become clinically relevant, it is important to demonstrate that stable long-term T-cell tolerance can be achieved using this approach. Recently, it has been shown that efficient expression of an allogeneic MHC class I gene in bone marrow-derived cells is sufficient to allow for permanent survival of MHC class I disparate skin grafts without affecting rejection of third-party grafts. 18 Cytotoxic T cells capable of lysing donor-type targets remained undetectable in vitro even after rigorous antigen challenge. These results are in contrast to previous studies in which T-cell hyporesponsiveness induced by genetic engineering of bone marrow could be broken by provision of T-cell help. These results suggest that donor-specific tolerance can be established by inducing molecular chimerism.
The mechanism by which induction of molecular chimerism induces CD8 T-cell tolerance has been recently elucidated using a T-cell receptor transgenic mouse model. In this system, H-2K b -specific transgenic CD8 T cells were observed to undergo negative selection in the thymus upon encountering bone marrow-derived cells expressing the transduced MHC class I gene. 19 Expression of the transduced antigen on T cells appears to participate in trafficking alloantigen to the thymus to facilitate negative selection, as suggested by a study that demonstrated that in the absence of transduced MHC class I expression on T and B cells, mice failed to become tolerant. 20 Since central deletion of alloreactive T cells is the most stable form of tolerance, the proof that deletion occurs in molecular chimeras is encouraging. Collectively, these data strongly suggest that gene therapy can be used to permanently reshape the T-cell repertoire.
Evidence for induction of regulatory cells that can prevent allograft rejection in gene therapy models
In recent years, a significant amount of evidence suggests that subpopulations of CD4 T cells can suppress allograft rejection. These regulatory cells can be induced using a variety of approaches including administration of nondepleting anti-CD4 antibodies and exposure to a tolerizing antigen in the form of donor-specific transfusions. [21] [22] [23] Often regulatory cells are able to induce tolerance to both the tolerizing antigen and third-party antigens, as long as they are both expressed on the same graft, suggesting that inhibition occurs locally. 21, 22 Recently, it has been shown that treatment of immunocompetent mice with nondepleting anti-T-cell antibodies together with syngeneic bone marrow infected with adenoviruses carrying an allogeneic MHC class I gene can lead to the acceptance of fully-allogeneic cardiac transplants which share the same MHC class I antigen carried by the adenovirus construct. 24 This approach essentially mimics results obtained using donor-specific transfusion, coupled with the use of nondepleting anti-Tcell antibodies to induce tolerance. Although the mechanism by which acceptance was achieved is unknown, transplant acceptance was observed even though gene expression was very short lived in vivo. These experiments suggest that the use of gene therapy-modified bone marrow may be capable of inducing regulatory T cells that can inhibit the responses to the transduced gene product as well as additional transplantation antigens when combined with other therapies. This is a potentially important extension of the use of molecular chimerism. However, it is not clear whether similar approaches would work in models in which the organ itself does not participate in the maintenance of tolerance, or prevent chronic rejection.
Induction of B-cell tolerance by molecular chimerism
In addition to inducing T-cell tolerance, molecular chimerism has been shown to be capable of inducing B-cell tolerance. Natural antibodies specific for the Gene therapy in organ transplantation J Bagley and J Iacomini carbohydrate epitope Gala1-3Galb1-4GlcNac-R (aGal) are the main mediators of hyperacute xenograft rejection in pig to primate xenotransplantation. Mutant mice, which lack a(1,3)galactosyltransferase (aGT), the enzyme that synthesizes the aGal epitope, produce aGal-specific natural antibodies, as do humans. Expression of porcine aGT in bone marrow-derived cells of aGT knockout mice has been shown to prevent the production aGal-reactive natural antibodies, resulting in stable long-term tolerance to aGal even after rigorous antigen challenge. 15, 25, 26 Importantly, tolerance remained intact even after mice received cardiac transplants from wild-type mice that expressed aGal, and aGal antibody-mediated rejection was prevented in molecular chimeras. 27 Analysis of B cells from mice reconstituted with aGT-transduced bone marrow revealed that B cells which produce aGalspecific antibodies were eliminated from the immunological repertoire following gene therapy. Collectively, these data suggest that gene therapy may be used to induce both B-and T-cell tolerance through the establishment of molecular chimerism.
Induction of tolerance in sensitized recipients
The extent to which pre-existing host immune responses can affect the induction of molecular chimerism and establishment of donor-specific tolerance is an important issue. Many patients have been presensitized to organ allografts by blood transfusions or previous transplants, and all humans have natural antibodies to aGal epitopes on xenogeneic organs. To determine the extent to which a preformed immune response was a barrier to the induction of molecular chimerism, aGT knockout mice were immunized with aGal-expressing pig cells. Since aGal is a T-dependent antigen 28 this immunization resulted in T-cell priming and increased titers of antiGal antibodies. Despite high titers of serum aGal-specific antibodies in immunized hosts, molecular chimerism could be established by increasing the dose of transduced bone marrow used for reconstitution of lethally irradiated recipient. 29 Once molecular chimerism was established in sensitized hosts, tolerance to aGal resulted and production of aGal-specific antibodies ceased. These data demonstrated that the induction of molecular chimerism could be used to reshape the pre-existing Bcell repertoire in appropriately conditioned sensitized hosts.
Gene therapy-mediated cytokine production, or immune deviation, prolongs graft survival, but does not prevent rejection Acute rejection events in immunosuppressed patients correlate with intragraft production of T helper type 1 (Th1) cytokines, such as IFN-g, while the lack of acute rejection is associated with production of T helper type 2 cytokines (Th2), such as IL-10. It has therefore been hypothesized that production of Th2 cytokines might act to downregulate the immune response to organ allografts. Thus, the concept of immune deviation was proposed as a way to prevent organ allograft rejection by fostering a Th2-type response, rather than Th1. Since systemic administration of cytokines often results in unacceptable side effects, gene therapy approaches were developed to test the hypothesis that modifying the local graft environment to promote Th2 rather than Th1 responses would result in prolonged transplant survival. The ability of several Th2-type cytokines to prolong allograft graft survival when expressed locally has been assessed both with and without additional immunosuppression. In general, prolongation of graft survival has been observed using this approach. However, expression of cytokine genes within donor tissues did not lead to permanent graft acceptance. More recently, it has been shown that localized liposome-mediated IL-10 gene transfer into rabbit cardiac transplants could induce alloreactive T-cell apoptosis and prolong cardiac allograft survival. 30 In addition, transfer of the gene encoding viral IL-10 delayed graft rejection in a rat model. 31 However, in both these studies, prolongation was extremely modest, and it is therefore unclear what kind of clinical significance can be attached to such results in model systems that are relatively sensitive to tolerance induction.
Transduction of dendritic cells with genes encoding immunomodulatory proteins can moderately prolong graft survival
An increased understanding of the role of dendritic cells in T-cell activation has led to an interest in modification of dendritic cells to induce tolerance. While mature dendritic cells express high levels of costimulatory molecules and induce strong T-cell responses, there is some evidence that dendritic cells expressing low levels of costimulatory molecules can induce anergy in Tcells. 32 Attempts have been made to modify graft rejection by genetically modifying dendritic cells to express cytokines associated with delayed graft rejection. Retroviral delivery of TGF-b into myeloid dendritic cells has been shown to decrease their ability to stimulate alloreactive cells, resulting in moderately prolonged graft survival of cardiac allografts in mice. 33 Human myeloid dendritic cells transduced with the gene encoding IL-10 prolonged human skin allograft survival in a humanized NOD-scid chimeric model. 34 However, other studies have indicated that adenovirus transduction of the IL-10 gene into murine myeloid dendritic cells can enhance alloreactive responses to cardiac grafts. 35 Overall, the results obtained with cytokine-gene-transduced dendritic cells were similar to those obtained with transduced organs. Both resulted in only a modest increase in transplant survival. Similar results have been observed in models where dendritic cells were transduced with genes encoding CTLA-4Ig. 36 Dendritic cells have also been genetically engineered to express Fas ligand (CD95L). [37] [38] [39] Engagement of Fas (CD95) on the surface of T cells by CD95L leads to the induction of apoptosis in activated T cells. Apoptosis induced by CD95/CD95L interactions is thought to play a role in the establishment of immunoprivileged sites such as the eye and testis, and may be involved in the killing of CD4 T cells. Dendritic cells genetically engineered to express CD95L on their surface are able to inhibit alloreactive T-cell proliferation in vitro, and cause a slight prolongation of cardiac graft survival Gene therapy in organ transplantation J Bagley and J Iacomini when administered in vivo. 38 However, as discussed above, since mouse cardiac transplants are relatively sensitive to tolerance induction, it is unclear how significant these results will be in more rigorous transplantation models.
Improved graft survival through antiapoptotic and antiproliferative gene therapy
In addition to host immunity, other nonimmunological factors play a role in transplant survival. Therefore, approaches have been developed to protect donor organ or tissue grafts at the time of transplantation from damage owing to nonimmune-mediated inflammation and ischemia-reperfusion injury. The use of gene transfer to prevent damage that occurs at the time of transplant has the advantage that it does not require long-term gene expression, making these therapies potentially clinically relevant.
A significant proportion of cellular transplants such as islets or hepatocytes are lost due to anoxia/ischemia reperfusion injuries at the time of transplantation that trigger the generation of reactive oxygen species leading to cellular death and localized inflammation. Endogenous scavenger systems can eliminate toxic radicals. However, the components of these systems are usually degraded rapidly when given exogenously. The expression of scavenging factors locally through genetic engineering of transplants would therefore be one way to protect organs and tissues. In a rat liver transplantation model, introduction of the gene encoding copperzinc superoxide dismutase through adenoviral transduction allowed for the survival of 100% of recipients, whereas only 25% of mock-treated controls survived. Expression of copper-zinc superoxide dismutase in transplanted livers also significantly reduced necrosis within the transplant. 40, 41 These data suggest that expression of copper-zinc superoxide dismutase decreases injury resulting from the generation of reactive oxygen species during transplantation. Similarly, gene therapy approaches using other cytoprotective genes such as hemeoxygenase-1 42, 43 and catalase 44 have also been shown to protect organs against the effects of ischemia-reperfusion. Expression of hemeoxygenase-1 in rat liver transplants following adenovirus-mediated gene transfer resulted in an increased survival of recipients from 50% in controls to 80% in those receiving hemeoxygenase-1-transduced livers. Gene transfer in these studies was performed from 4 to 24 h in advance of transplant, which may be compatible with clinical application of these techniques.
The overexpression of antiapoptotic genes in transplanted tissue may also protect the graft from Figure 1 Preventing transplant rejection by gene therapy. Gene therapy-based strategies can be used to prevent activation of alloreactive host T cells in peripheral lymphoid tissue, such as the lymph node (shown), by blocking costimulatory molecule interactions between T cells and APCs (a). Such interventions leave T cells in a non-responsive state, and can also result in anergy. Reconstitution of conditioned hosts with autologous hematopoietic stem cells engineered to express donor type transplantation antigens using retroviruses allows for expression of donor type antigen on bone marrow-derived cells (b). Expression of retrovirally transduced antigen on bone marrow-derived cells within the recipient thymus mediates negative selection of newly formed alloreactive T cells (c). It is unclear whether expression in the thymus can also lead to the generation of regulatory T cells capable of controlling allograft rejection. Direct modification of the donor graft itself (d) using a wide variety of gene delivery systems prior to transplantation offers the possibility of reducing graft damage owing to ischemia-reperfusion injury. This approach has also been proposed as a method to allow the destruction of alloreactive T cells that reach the graft.
Gene therapy in organ transplantation J Bagley and J Iacomini nonimmune as well as immune-mediated injury. Bcl-2, an antiapoptotic cell survival factor, blocks the release of cytochrome 3 from the mitochondria and subsequent activation of caspases, proteases involved in cell death. The overexpression of bcl-2 in macaque pancreatic islets was able to enhance insulin production after transplant into diabetic SCID mice 45 and protect porcine islets after exposure to rhesus monkey serum. 46 In addition, the expression of bcl-2 protected human endothelial cells from CTL activity. 47 However, since the function of bcl-2 is intracellular, the effectiveness of this approach is dependent on a high transduction efficiency that will be more difficult to achieve in the terminally differentiated cells of vascularized organs.
Prospects
In the coming years, in order for gene therapy to be used to prevent transplant rejection clinically, it will be crucial to gain a better understanding of how alloreactive T cells are activated and regulated, so that rational gene therapy interventions can be designed to prevent transplant rejection (Figure 1 ).
Blockade of yet to be defined costimulatory pathways needs to be evaluated in order to determine if targeting these pathways using gene therapy approaches will exhibit utility for clinical transplants. In addition, a greater understanding of the mechanisms by which regulatory T cells are induced needs to be achieved in order to design strategies to exploit these cells to achieve transplant acceptance. Tolerance induction remains a major goal in the field, and if it can be achieved clinically may represent the most attractive approach, completely overcoming the need for immunosuppression. Results obtained in molecular chimeras have demonstrated that gene therapy approaches can be used to induce tolerance. Coupling the induction of molecular chimerism to, for instance, induction of regulatory cells may allow for survival of organs mismatched at major and minor histocompatibility loci, extending the clinical utility of this approach. However, the ability of molecular chimerism to induce tolerance must also be assessed in preclinical non-human primate models to determine if similar approaches could eventually be used in humans. In addition, methods must be developed to allow the induction of molecular chimerism using clinically acceptable host conditioning. Lastly, as has been true for many years, the development of more efficient vectors for gene transfer continues to be of great importance, allowing for more efficient transduction and improved gene expression.
